Industry News

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• SS Innovations Showcases SSi Mantra Telesurgery Capabilities Across Intercontinental and Multidisciplinary Demonstrations: Reported by OrthoSpineNews, SS Innovations demonstrated its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console in live telesurgeries performed in October 2026 across 7,500 miles (12,000 kilometers) between Barcelona and Bengaluru, alongside four multidisciplinary telesurgical procedures completed at SRS India.
• Kuros Biosciences Reports 40 Percent Year-Over-Year Sales Surge Driven by MagnetOs Bone Graft Adoption: Reported by Orthopedics This Week, Swiss orthobiologics company Kuros Biosciences achieved product sales of $141.8 million for the nine months ended September 2026, representing a 40 percent increase over $101.1 million in the corresponding prior-year period driven by expanding surgical adoption of its MagnetOs bone graft.
• Next-Generation Metal Additive Platforms Accelerate Industrial Scaling of Porous Orthopaedic Implants: Reported by BONEZONE, additive manufacturing platforms from AddUp and Tecomet deploy multi-laser powder bed fusion and vacuum electron beam melting architectures to scale production of biomimetic porous lattices with enhanced osseointegration for joint reconstruction.
• SurGenTec, LLC Obtains 510(k) Clearance for Vantage Lumbar Decompression Kit: SurGenTec, LLC received FDA 510(k) clearance (K263208) for its Vantage Lumbar Decompression Kit, indicated for manual lumbar spine decompression.
• Spinal Simplicity, LLC Obtains 510(k) Clearance for Minuteman G6 MIS Fusion Plate & Patriot SI Implant System: Spinal Simplicity, LLC secured FDA 510(k) clearance (K261607) for its Minuteman G6 MIS Fusion Plate and Patriot SI Implant System, indicated for interspinous and sacroiliac joint fusion.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

SS Innovations International, Inc.: SS Innovations Showcases SSi Mantra Telesurgery Capabilities Across Intercontinental and Multidisciplinary Demonstrations

• Summary: SS Innovations International, Inc. announced that its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were successfully showcased in live telesurgeries performed in October 2026 during the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain and the Society of Robotic Surgery India (SRS India) Conference in New Delhi, India. At EACTS, Dr. Sudhir Srivastava performed a robotic-assisted cardiac telesurgery utilizing the SSi Mantra and SSi MantrAsana console live on stage in Barcelona, operating on a patient 7,500 miles (12,000 kilometers) away at Sri Madhusudan Sai Institute in Bengaluru, India with patient-side support from Dr. Lalit Malik. At SRS India, four surgeons completed four separate robotic-assisted telesurgeries, including a right partial nephrectomy, right hemicolectomy, left-sided pediatric pyeloplasty, and radical hysterectomy with sentinel lymph node biopsy. The SSi MantrAsana console is engineered for real-time remote procedures through ultra-low latency connectivity, high-definition 3D visualization, and ergonomic master controls designed to expand specialized surgical reach to remote and underserved operating environments.
• Key Details:
  • Device/System Name: SSi Mantra Surgical Robotic System and SSi MantrAsana Tele-Surgeon Console
  • Status: Live Clinical Telesurgery Demonstrations Showcased (40th EACTS and Inaugural SRS India)
  • Clinical Significance: Demonstrates the clinical viability of long-distance robotic telesurgery across low-latency network architectures, highlighting the potential for high-volume academic centres to provide subspecialty operative guidance and intervention to remote community hospitals without surgeon travel.
• Original Source: OrthoSpineNews

Spine & Orthobiologics

Kuros Biosciences: Kuros Biosciences Reports 40 Percent Year-Over-Year Sales Surge Driven by MagnetOs Bone Graft Adoption

• Summary: Swiss-based orthobiologics company Kuros Biosciences reported product sales of $141.8 million for the nine months ended September 2026, representing a 40 percent increase from $101.1 million reported in the corresponding prior-year period. Revenue acceleration was primarily driven by continuing commercial adoption of its MagnetOs bone graft portfolio across spine and orthopaedic surgery. MagnetOs features proprietary NeedleGrip submicron surface architecture that promotes osteopromotion and bone formation without exogenous osteoinductive growth factors. The sustained financial growth reflects expanding clinical utilization by spine surgeons seeking reliable osteoinductive alternatives in complex spinal fusions.
• Key Details:
  • Device/System Name: MagnetOs Bone Graft (NeedleGrip Surface Technology)
  • Status: Nine-Month 2026 Financial Results and Commercial Expansion
  • Clinical Significance: Provides commercial and clinical validation for submicron surface-structured osteoinductive synthetic bone grafts, offering surgeons an evidence-backed alternative to recombinant BMPs and autograft harvest while reducing donor site morbidity.
• Original Source: Orthopedics This Week

Joint Reconstruction

AddUp and Tecomet: Next-Generation Metal Additive Platforms Accelerate Industrial Scaling of Porous Orthopaedic Implants

• Summary: BONEZONE reported on the rapid evolution of additive manufacturing platforms meeting complex engineering and volume production needs in orthopaedics. Advanced platforms from manufacturers including AddUp and Tecomet are deploying multi-laser powder bed fusion (LPBF) architectures featuring up to four lasers and expanded build plates, reducing setup and changeover times while scaling output. In parallel, electron beam melting (EBM) platforms printing in high-temperature vacuum enclosures minimize residual thermal stresses and supportless printing, enabling direct integration of biomimetic porous lattices that replicate traditional sintered and plasma-spray porous coatings with higher shear strength and accelerated biological osseointegration.
• Key Details:
  • Device/System Name: Multi-Laser LPBF and Vacuum EBM Additive Manufacturing Platforms
  • Status: Technical Appraisal and Industrial Production Scaling (BONEZONE)
  • Clinical Significance: Enables commercial-scale production of anatomically contoured implants with gradient porosity and trabecular lattices, improving initial press-fit stability and biological osseointegration while lowering manufacturing costs across primary and revision arthroplasty systems.
• Original Source: BONEZONE

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES: ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2 to 4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.